Outcome of Board Meeting

Emcure Ref: EPL/CS/SE/0094/2026 Date: November 03, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Outcome of Board Meeting held on November 03, 2026. In continuation to our letter dated October 14, 2026, and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), read with Schedule III of aforesaid Regulations and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, November 03, 2026, has inter-alia transacted and approved Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the SEBI Listing Regulations, we are enclosing herewith the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026, along with the Limited Review Reports on the aforesaid Results as issued by M/s. B S R & Co. LLP, Chartered Accountants, Statutory Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026, is also enclosed herewith as Annexure B. The meeting of the Board of Directors of the Company commenced at 12:48 p.m. (IST) and concluded at 13:30 p.m. (IST). You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership No.: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Annexure - A 8th Floor, Unit 802, Godrej Koregaon Park BS R & Co. LLP North Main Road, Mundhwa Pune, Maharashtra, 411001 Chartered Accountants Telephone: +91 (20) 4061 2200 Limited Review Report on unaudited consolidated financial results of Emcure Pharmaceuticals Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Emcure Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Emcure Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting'' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 241 O "Review of Interim Financial Information Performed by the Independent Auditor of the Entity'', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The Statement includes the interim financial information of 18 Subsidiaries which have not been reviewed, whose interim financial information reflects total assets (before consolidated adjustments) of INR 13,653 million as at 30 September 2026 and total revenues (before consolidated adjustments) of INR 2,633 million and INR 5,479 million, total net profit after tax (net) (before consolidated adjustments) of INR 19 million and INR 112 million and total comprehensive income (nett(-before consolidated adjustments) of INR 29 million and INR 172 million, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustments) of Rs 136 million for the period from 1 April 2026 to 30 Saal'lft'!1rm,,-.._ 2026 as considered in the Statement. According to the information and explanations • ~ t the Parent's management, these interim financial information are not material to the Registered Office: BS R & Co. (a partne,ship fim, with Registration No. BA61223) converted into BS R & Co. LLP (a l~lh Flnor. C,enlta! B WJnv and onh C 'Mli!~ ~ Limited Uahitty Partnership wilh Ll.P Registration No. AAB-8181) with effect from OdDber 14, 2013 Cenler, W""1em ElClifess Hlghv,-ay, G<,n,go 8 S R&Co. LLP Limited Review Report (Continued) Emcure Pharmaceuticals Limited Our conclusion is not modified in respect of this matter. For B S R & Co. LLP Chartered Accountants Finn's Registration No.:101248W/W-100022 Partner Pune Membership No.: 062343 03 November 2026 UDIN:26062343AMLWQR6900 Page 2 of4 BS R & Co. LLP Limited Review Report (Continued) Emcure Pharmaceuticals Limited Annexure I List of entities included in unaudited consolidated financial results: Sr. No Name of component Relationship 1 Emcure Pharmaceuticals Limited ("EPL~) Parenti Holding Company 2 Zuventus Healthcare Limited Subsidiary of EPL 3 Gennova Biopharmaceuticals Limited Subsidiary of EPL 4 Emcure Pharmaceuticals Pty Ltd Subsidiary of EPL 5 Emcure Nigeria Limited Subsidiary of EPL 6 Emcure Pharmaceuticals Mena FZ LLC Subsidiary of EPL 7 Emcure Pharmaceuticals South Africa (Pty) Limited Subsidiary of EPL 8 Emcure Brasil Farmaceutica Ltda Subsidiary of EPL 9 Emcure Pharma UK Ltd ("EPUK") Subsidiary of EPL 10 Emcure Pharma Peru S.A.C. Subsidiary of E [Showing first 8,000 characters — download PDF for full document]